share_log

5 Value Stocks In The Healthcare Sector

5 Value Stocks In The Healthcare Sector

5 醫療保健行業的價值股票
Benzinga Real-time News ·  2023/01/09 09:44

What are Value Stocks?

什麼是價值股?

A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.

與同行業公司的股票價格相比,價值股票的價格通常較低。這表明該公司的價值可能被低估,因為投資者並沒有對此類公司表達盡可能多的興趣。檢查價值的最常用方法是使用價格對盈利倍數或市盈率(P/E 倍數)。低 P/E 倍數表明股票價值被低估。

Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:

本辛加洞察已經編制了醫療保健行業的價值股清單,這些股票可能值得關注:

  1. Cullinan Oncology (NASDAQ:CGEM) - P/E: 4.94
  2. ProPhase Labs (NASDAQ:PRPH) - P/E: 5.17
  3. ITeos Therapeutics (NASDAQ:ITOS) - P/E: 2.64
  4. Procaps Gr (NASDAQ:PROC) - P/E: 7.77
  5. Kiniksa Pharmaceuticals (NASDAQ:KNSA) - P/E: 7.78
  1. 天璽腫瘤科 (納斯達克:克寶石)-P/E:4.94
  2. ProPhase 實驗室 (納斯達克:普爾夫)-P/E:5.17
  3. ITEOS 治療學 (納斯達克:它)-P/E: 2.64
  4. 處理 GR (納斯達克:過程)-P/E:7.77
  5. 金尼克萨制药 (納斯達克:尼薩)-P/E:7.78

Cullinan Oncology saw a decrease in earnings per share from 3.77 in Q2 to $-0.54 now. ProPhase Labs saw a decrease in earnings per share from 0.4 in Q2 to $0.06 now. ITeos Therapeutics's earnings per share for Q3 sits at $0.03, whereas in Q2, they were at 0.15. Procaps Gr's earnings per share for Q3 sits at $0.22, whereas in Q2, they were at -0.07. Kiniksa Pharmaceuticals has reported Q3 earnings per share at $3.18, which has increased by 1196.55% compared to Q2, which was -0.29.

庫里南腫瘤學的每股盈利從第二季度的 3.77 下降至 -0.54 美元。ProPhase 實驗室現在每股盈利從第二季度的 0.4 減少到 0.06 美元。ITEOS 治療學第三季度的每股收益為 0.03 美元,而第二季度則為 0.15 美元。在第三季度,Gr 的每股收益為 0.22 美元,而在第二季度,則為 -0.07。金尼克薩製藥公司報告了第三季度每股盈利為 3.18 美元,與第二季度相比增加了 1196.55%,這是 -0.29。

These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.

這 5 種價值股票是由 營運洞察 基於量化分析。儘管這種有條不紊的判斷過程並不意味著做出最終決定,但我們的技術可以為投資者提供額外的認知。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論